People | October 13, 2025
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Several technologies for hemoglobinopathies are being transferred to commercial partners
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
India currently hosts more than 10,075 biotech startups
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated
